Mertansine (DM1)
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 123212

CAS#: 139504-50-0

Description: Mertansine refers to the thiol-containing maytansinoid, DM1 (N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) attached to a monoclonal antibody through reaction of the thiol group with an SPP (N-succinimidyl 4-(2-pyridyldithio)) linker to create an antibody-drug conjugate or ADC. Experimental ADCs with the SPP-DM1 design include lorvotuzumab mertansine. DM1 can also be linked to an antibody using the SMCC (4-(3-mercapto-2,5-dioxo-1-pyrrolidinylmethyl)-cylohexanecarboxylic acid) linker, in which case the International Nonproprietary Name of the conjugate formed contains the word emtansine. DM1 and its attachment via these linkers result from ImmunoGen Inc research. Trastuzumab emtansine (T-DM1) is an anti-HER2/neu antibody-drug conjugate.

Chemical Structure

img
Mertansine (DM1)
CAS# 139504-50-0
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 123212
Name: Mertansine (DM1)
CAS#: 139504-50-0
Chemical Formula: C35H48ClN3O10S
Exact Mass: 737.27
Molecular Weight: 738.290
Elemental Analysis: C, 56.94; H, 6.55; Cl, 4.80; N, 5.69; O, 21.67; S, 4.34

Price and Availability

Size Price Availability Quantity
10mg USD 150 Ready to ship
25mg USD 300 Ready to ship
50mg USD 450 Ready to ship
100mg USD 750 Ready to Ship
200mg USD 1250 Ready to Ship
500mg USD 2650 Ready to Ship
1g USD 4550 Ready to ship
Bulk inquiry

Synonym: DM1; DM-1; DM 1; DM1 Compound; DM1 [Maytansinoid]; Maytansinoid DM 1; Maytansinoid DM1; Maytansinoid DM-1; UNII-DDZ29HGH0E; maytansine, Mertansine; emtansine;

IUPAC/Chemical Name: (14S,16S,33S,2R,4R,10E,12Z,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-(3-mercaptopropanoyl)-N-methyl-L-alaninate

InChi Key: ANZJBCHSOXCCRQ-GCRZMMRQSA-N

InChi Code: InChI=1S/C35H48ClN3O10S/c1-19-10-9-11-26(46-8)35(44)18-25(47-33(43)37-35)20(2)31-34(4,49-31)27(48-32(42)21(3)38(5)28(40)12-13-50)17-29(41)39(6)23-15-22(14-19)16-24(45-7)30(23)36/h9-11,15-16,20-21,25-27,31,44,50H,12-14,17-18H2,1-8H3,(H,37,43)/b11-9-,19-10+/t20-,21+,25+,26-,27-,31?,34+,35+/m1/s1

SMILES Code: C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C\C=C(\CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@H]([C@]4(C1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCS)C)/C)OC)(NC(=O)O2)O

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Mertansine is a tubulin inhibitor, meaning that it inhibits the assembly of microtubules by binding to tubulin (at the rhizoxin binding site). The monoclonal antibody binds specifically to a structure (usually a protein) occurring in a tumour, thus directing mertansine into this tumour. This concept is called targeted therapy. The following (experimental) drugs are antibody-drug conjugates (ADC) combining monoclonal antibodies with mertansine as the cytotoxic component. Mertansine is linked via 4-mercaptovaleric acid.

Biological target: Mertansine (DM1) is a microtubulin inhibitor and an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.
In vitro activity: DM1 is a synthetic derivative of the tubulin-binding agent maytansine. Maytansine and the DM1 (S-methyl-DM1; ((N2’-deacetyl-N2’-(3-thiomethyl-1-oxopropyl)-maytansine; Fig. 1) suppress microtubule dynamics at very low drug concentrations. Maytansine as well as the DM1 derivative strongly suppress the dynamic instability parameters of microtubules assembled from MAP-free tubulin in vitro (Fig. 2). Maytansine and S-methyl-DM1 suppressed almost all dynamic instability parameters, including the growth rate, the shortening rate, the catastrophe frequency, and the rescue frequency, with the DM1 derivative showing stronger suppression of dynamics than the parent macrolide. The molecular mechanism of action of S-methyl-DM1 was found to be microtubule end poisoning. That is, S-methyl DM1 binds to the tips of microtubules and thereby inhibits the growth and the shortening of microtubules, leading to suppression of microtubule dynamics. Specifically, the maytansinoid showed high-affinity binding (KD, 0.1 μmol/L ) to approximately 37 sites per microtubule. Reference: Cancer Lett. 2011 Aug 28;307(2):113-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105156/
In vivo activity: cRGD-decorated, redox-activatable micellar mertansine prodrug (cRGD-MMP) can effectively target and deliver DM1 to αvβ3 integrin overexpressing MDA-MB-231 TNBC xenografts in nude mice, resulting in potent tumor growth inhibition. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays showed that cRGD-MMP had obvious targetability to MDA-MB-231 cells with a low half-maximal inhibitory concentration (IC50) of 0.18 μM, which was close to that of free DM1 and 2.2-fold lower than that of micellar mertansine prodrug (MMP; nontargeting control). The confocal microscopy studies demonstrated that cRGD-MMP mediated a clearly more efficient cellular uptake and intracellular release of doxorubicin (used as a fluorescent anticancer drug model) in MDA-MB-231 cells. Notably, cRGD-MMP loaded with 1,1'-dioctadecyltetramethyl indotricarbocyanine iodide (DiR; a hydrophobic near-infrared dye) was shown to quickly accumulate in the MDA-MB-231 tumor with strong DiR fluorescence from 2 to 24 h post injection. MMP loaded with DiR could also accumulate in the tumor, although significantly less than cRGD-MMP. The biodistribution studies revealed a high DM1 accumulation of 8.1%ID/g in the tumor for cRGD-MMP at 12 h post injection. The therapeutic results demonstrated that cRGD-MMP effectively suppressed MDA-MB-231 tumor growth at 1.6 mg DM1 equiv./kg without causing noticeable side effects, as shown by little body weight loss and histological analysis. This MMP has appeared as a promising platform for potent treatment of TNBCs. Reference: Int J Nanomedicine. 2017 Oct 27;12:7913-7921. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667790/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 60.0 81.26

Preparing Stock Solutions

The following data is based on the product molecular weight 738.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011 Aug 28;307(2):113-8. doi: 10.1016/j.canlet.2011.03.017. Epub 2011 Apr 9. PMID: 21481526; PMCID: PMC3105156. 2. Zhong P, Gu X, Cheng R, Deng C, Meng F, Zhong Z. αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo. Int J Nanomedicine. 2017 Oct 27;12:7913-7921. doi: 10.2147/IJN.S146505. PMID: 29138558; PMCID: PMC5667790.
In vitro protocol: 1. Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011 Aug 28;307(2):113-8. doi: 10.1016/j.canlet.2011.03.017. Epub 2011 Apr 9. PMID: 21481526; PMCID: PMC3105156.
In vivo protocol: 1. Zhong P, Gu X, Cheng R, Deng C, Meng F, Zhong Z. αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo. Int J Nanomedicine. 2017 Oct 27;12:7913-7921. doi: 10.2147/IJN.S146505. PMID: 29138558; PMCID: PMC5667790.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Koniev O, Kolodych S, Baatarkhuu Z, Stojko J, Eberova J, Bonnefoy JY, Cianférani S, Van Dorsselaer A, Wagner A. MAPN: First-in-Class Reagent for Kinetically Resolved Thiol-to-Thiol Conjugation. Bioconjug Chem. 2015 Sep 3. [Epub ahead of print] PubMed PMID: 26335849.

2: Van den Mooter T, Teuwen LA, Rutten A, Dirix L. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. Expert Opin Biol Ther. 2015 May;15(5):749-60. doi: 10.1517/14712598.2015.1036026. PubMed PMID: 25865453.

3: Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, Wang F, Diesl V, Follettie MT, Musto S, Lam MH, Hu W, Charati MB, Khandke K, Kim KS, Cinque M, Lucas J, Graziani E, Maderna A, O'Donnell CJ, Arndt KT, Gerber HP. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015 Apr;14(4):952-63. doi: 10.1158/1535-7163.MCT-14-0862. Epub 2015 Feb 2. PubMed PMID: 25646013.

4: Robak T, Robak E. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2014 Jul;23(7):911-24. doi: 10.1517/13543784.2014.908184. Epub 2014 Apr 7. Review. PubMed PMID: 24708159.

5: Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. doi: 10.4161/mabs.27756. Epub 2014 Jan 8. PubMed PMID: 24492307; PubMed Central PMCID: PMC3984343.

6: Berdeja JG. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. Front Biosci (Landmark Ed). 2014 Jan 1;19:163-70. Review. PubMed PMID: 24389179.

7: Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014 Aug 1;16(4):419. doi: 10.1186/s13058-014-0419-5. Erratum in: Breast Cancer Res. 2014;16(6):468. PubMed PMID: 25928889; PubMed Central PMCID: PMC4429364.

8: Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Nov;60(11):1860-7. doi: 10.1002/pbc.24647. Epub 2013 Jun 24. PubMed PMID: 23798344; PubMed Central PMCID: PMC4260400.

9: van de Donk NW, Lokhorst HM. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother. 2013 Aug;14(12):1569-73. doi: 10.1517/14656566.2013.805746. Epub 2013 May 31. PubMed PMID: 23721099.

10: Ballantyne A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs. 2013 May;73(7):755-65. doi: 10.1007/s40265-013-0050-2. Review. PubMed PMID: 23620199.

11: Pode-Shakked N, Shukrun R, Mark-Danieli M, Tsvetkov P, Bahar S, Pri-Chen S, Goldstein RS, Rom-Gross E, Mor Y, Fridman E, Meir K, Simon A, Magister M, Kaminski N, Goldmacher VS, Harari-Steinberg O, Dekel B. The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. EMBO Mol Med. 2013 Jan;5(1):18-37. doi: 10.1002/emmm.201201516. Epub 2012 Dec 13. PubMed PMID: 23239665; PubMed Central PMCID: PMC3569651.

12: Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044. Review. PubMed PMID: 23173552; PubMed Central PMCID: PMC3731599.

13: Beck A, Lambert J, Sun M, Lin K. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs. 2012 Nov-Dec;4(6):637-47. doi: 10.4161/mabs.21697. Epub 2012 Aug 22. PubMed PMID: 22909934; PubMed Central PMCID: PMC3502230.

14: Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J. 2012 Dec;14(4):799-805. doi: 10.1208/s12248-012-9386-x. Epub 2012 Aug 9. Review. PubMed PMID: 22875610; PubMed Central PMCID: PMC3475867.

15: Gurtner K, Hessel F, Eicheler W, Dörfler A, Zips D, Heider KH, Krause M, Baumann M. Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother Oncol. 2012 Mar;102(3):444-9. doi: 10.1016/j.radonc.2011.10.013. Epub 2011 Nov 17. PubMed PMID: 22100655.

16: Ricart AD. Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther. 2011 Apr;89(4):513-23. doi: 10.1038/clpt.2011.8. Epub 2011 Mar 2. Review. PubMed PMID: 21368753.

17: Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008 Jul-Aug;5(4):474-86. doi: 10.1021/mp800024g. Epub 2008 Jun 3. Review. PubMed PMID: 18547053; PubMed Central PMCID: PMC2772999.

18: Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol. 2008 Oct;62(5):911-9. doi: 10.1007/s00280-007-0672-8. Epub 2008 Feb 27. PubMed PMID: 18301896.

19: Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008 Sep;44(9):823-9. doi: 10.1016/j.oraloncology.2007.10.009. Epub 2008 Jan 18. PubMed PMID: 18203652.

20: Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, Staab A, Hanft G, Huober J, Sinn HP, Sohn C, Schneeweiss A. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs. 2007 Apr;18(4):477-85. PubMed PMID: 17351401.